KRAS and non-small cell lung carcinoma: Recent advancements are highlighted by sotorasib, a small molecule inhibitor specifically targeting the KRAS G12C mutant protein, which is prevalent in non-small cell lung cancer (NSCLC) [313], pancreatic cancer [314], and colorectal cancer [315].